MedTrace Logo

Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

NCT03488472 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-05-06

Study results available
· View outcomes & findings →

Summary

This study is a prospective single arm trial designed to study the safety and effectiveness of a medical device, NovoTTF-200A, used with stereotactic radiosurgery (SRS) in subjects with brain metastases from small cell lung cancer (SCLC).

Conditions

Interventions

DEVICE

NovoTTF-200A

Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.

RADIATION

Stereotactic Radiosurgery (SRS)

SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.

Sponsors & Collaborators

  • NovoCure Ltd.

    collaborator INDUSTRY

  • Drexell Hunter Boggs

    lead OTHER

Principal Investigators

  • Drexell H Boggs, MD · University of Alabama at Birmingham (UAB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-09
Primary Completion
2022-02-15
Completion
2022-02-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488472 on ClinicalTrials.gov